• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 18th September 2012

Advances in Oncology Modelling: Recent Results from POI Research

OHE and the Pharmaceutical Oncology Initiative (POI) held a workshop to discuss and debate several key issues in oncology modelling. Participating were more than 50 experts from industry, academia and government. The focus of the workshop was three key technical…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
seminar-meeting5-5-10

OHE and the Pharmaceutical Oncology Initiative (POI) held a workshop to discuss and debate several key issues in oncology modelling. Participating were more than 50 experts from industry, academia and government. The focus of the workshop was three key technical challenges associated with using clinical trial data for anti-cancer medicines and adapting it, in an unbiased fashion, to support decisions about cost-effectiveness.

Advances in Oncology Modelling: Recent Results from POI Research

OHE and the Pharmaceutical Oncology Initiative (POI)[1] held a workshop to discuss and debate several key issues in oncology modelling.  Participating were more than 50 experts from industry, academia and government.

The focus of the workshop was three key technical challenges associated with using clinical trial data for anti-cancer medicines and adapting it, in an unbiased fashion, to support decisions about cost-effectiveness.  These are: extrapolating from progression-free survival, correcting for patient crossover, and efficient modelling of different sequences of treatment.

Based on research commissioned by the POI, Prof Neil Hawkins of Oxford Outcomes discussed the problems raised by extrapolating from clinical trial data that captures “progression-free survival”  to calculate “overall survival”.  The latter is required to assess changes in quality adjusted life years (QALYs).

Among the issues considered were the multiple types of uncertainty that characterise clinical trial data and the dangers of naïve extrapolation or “testimation”, where observed trial data are used to select among competing model choices post hoc.  Prof Hawkins called for a careful weighing of the available models for extrapolation and for involvement of health technology assessment (HTA) policy makers early in the extrapolation process.

A potentially promising approach identified by Prof Hawkins is increased collection and use of additional output data during clinical trials for the purpose of helping to solidify understanding of the complex relationships among outcomes in different trial populations.  This approach ultimately may be used to develop an improved approach to modelling that integrates under-observed trial outcomes into overall survival estimates, as a way to provide regulatory authorities with the measures they need to decide whether to approve a new drug.

Prof Andrew Briggs of the University of Glasgow presented a case study that provides another perspective on overall and progression-free survival.  He also suggested the use of more general methods of analysis, such as multi-state survival analysis, that permit the direct estimation of both overall survival and progression-free survival from the trial data.

Nicholas Latimer, from ScHARR at the University of Sheffield, discussed the results of a study commissioned by POI that focuses on methods for adjusting survival estimates in the presence of treatment crossover.  This statistical problem arises when ethical considerations require that clinical trial participants be permitted to “cross over” to alternative branches of a trial once preliminary data has demonstrated that they would benefit from the alternative treatment.  This non-random migration from the original allocation complicates analysis of the results produced in trials if a substantial degree of crossover occurs.

The ScHARR POI study is based on a simulation that used hypothetical patient groups.  It was meant to test a number of statistical techniques including popular, but potentially unsound approaches, such as simply discarding data from crossed-over patients.  The results of the 72 scenarios tested showed significant differences in effectiveness for the various correction methods depending on the number of patients that crossed over and whether the new treatment was less effective in patients who crossed over later in the progression of the disease.  While no single “best” approach to correction was identified, certain approaches did perform poorly consistently. Determining which method is likely to produce the least bias may be possible through analysis of the treatment crossover mechanism and the clinical trial dataset.

Dr Martin Hoyle of PenTAG provided an alternative view on the problem of treatment crossover based on his direct experience in evidence review.  He emphasised the importance of being pragmatic in choosing among various methods and the importance of model choice in each case.

A moderated panel discussion featured brief presentations from representatives of industry, government and academia on the difficulties of modelling treatment sequences, an issue that arises when patients in a clinical trial receive a number of treatments in different sequences.  This produces data that are difficult to incorporate parsimoniously into HTA models.  A general discussion that involved the audience identified existing options for extracting the effect of individual medicines from sequenced data. This will provide the starting point for a working paper to be completed for POI this year.

The workshop concluded with a panel discussion exploring how insights from the two studies conducted for POI by Oxford Outcomes and ScHARR could inform current UK HTA processes.  Participating were Peter Donnan of the University of Dundee, a member of the NDC Committee of the Scottish Medicines Consortium, and Helen Knight and Meindert Boysen from NICE.

 

[1] The POI is a group of pharmaceutical companies, all members of the Association of the British Pharmaceutical Industry, that work with and support the NHS in improving the delivery of cancer services. http://www.abpi.org.uk/our-work/value-access/groups/Pages/poi.aspx

 

  • Drug Development/R&D
  • Events

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • January 2020

OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?

Read more
  • News
  • September 2019

OHE Lunchtime Seminar: Closing the ‘Know-do’ Gap for Health Systems Reform at the Policy Level

Read more
  • News
  • August 2019

OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!